

May 1, 2008
APA DSM-V Work Group Member

Name, Degree: Hans Ulrich Wittchen, Ph.D.
Role(s) in Work Group: Member, Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorders Work Group
Institutional Affiliation(s): Director, Institute of Clinical Psychology and Psychotherapy, Technische Universitaet
City, State: Dresden, Germany

Biographical Sketch:

Dr. Wittchen is Director of the Institute of Clinical Psychology and Psychotherapy, and the Center of Clinical Epidemiology and Longitudinal Studies (CELOS) at the Technische Universitaet Dresden, Germany. He is also Honorary Professor at the LMU in München and still serves of consultant of the Max Planck Institute of Psychiatry (München), where he has been Head of Department prior to his current position. As a clinician and researcher his main interest is experimental and clinical epidemiological research on the aetiological pathways of anxiety, substance and depressive disorders, comorbidity, diagnostic classification and assessment instruments. His research covers large-scale national and international cross-sectional and longitudinal studies in the community on the national course of mental disorders and their impact. He is and has been principal investigator or collaborator on various major national and international study programs such as the WHO collaborative primary care study, the EDSP and the NCS. He served as consultant to the World Health Organization (WHO) in the field of diagnostic assessment and has been Co-PI in the development of various diagnostic instruments like the Composite International Diagnostic Interview (CIDI) or the SCID. He is also Secretary and Council member of the European College of Neuropharmacology (ECNP) and has been responsible for the European Brain Council (EBC) study on "Size, Burden and Costs of Disorders of the Brain in Europe. Dr. Wittchen is also Editor or on the editorial board of several high impact peer review journals, such as the International Journal of Methods in Psychiatric Research, Psychological Medicine, Drug and Alcohol Dependence and Addiction. Dr. Wittchen received his PhD in Psychology at the University of Vienna (1975) and his Dr. phil. habil. at the Ludwig-Maximilians- Universitaet (LMU) in Munich.

UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : **CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008**, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

Non-Profit and Advocacy Organizations	Year(s)	Role
European College of Neuropsychopharmacology (ECNP)	2005-2010	Secretary and member of Council
Lundbek Foundation	2005-2007	Member, Board of Advisors

The two tables below represent Dr. Wittchens' disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. Wittchen has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted

research grants) will not exceed \$10,000 in any calendar year.

<p>KEY NUMBER:</p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---	--

DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007

Commercial or Other Organization	Year(s)	Key #(s)
Pfizer	2005-2007	1, 3, 4
Sanofi-Aventis	2005-2007	1
Eli Lilly	2006-2007	3, 4
Organon/Schering Plough	2005-2007	1
Novartis	2005-2007	3, 4
Lundbeck Foundation	2005-2007	1, 4, 10 (travel)

DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR

Commercial or Other Organization	Year(s)	Key #(s)
Sanofi-Aventis	2008	1
Pfizer Germany and US	2008	1
Sanofi-Aventis	2008	1
Lundbek	2008	1, 4
Pfizer	2008	1, 4
Eli Lilly	2008	4
Novartis	2008	1, 3, 4